WO2008050133A3 - Inhibition of beta-amyloid aggregation - Google Patents

Inhibition of beta-amyloid aggregation Download PDF

Info

Publication number
WO2008050133A3
WO2008050133A3 PCT/GB2007/004079 GB2007004079W WO2008050133A3 WO 2008050133 A3 WO2008050133 A3 WO 2008050133A3 GB 2007004079 W GB2007004079 W GB 2007004079W WO 2008050133 A3 WO2008050133 A3 WO 2008050133A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
beta
amyloid aggregation
aggregation
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/004079
Other languages
French (fr)
Other versions
WO2008050133A2 (en
Inventor
Jesus Zurdo
Susan Fowler
Ernest Giralt
Meritxell Teixido
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZYENTIA Ltd
Original Assignee
ZYENTIA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZYENTIA Ltd filed Critical ZYENTIA Ltd
Priority to EP07824323A priority Critical patent/EP2089419A2/en
Publication of WO2008050133A2 publication Critical patent/WO2008050133A2/en
Publication of WO2008050133A3 publication Critical patent/WO2008050133A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to the peptidyl inhibitors of ABeta1-42 aggregation. These inhibitors may be useful, for example, in the treatment of Alzheimer's disease
PCT/GB2007/004079 2006-10-27 2007-10-26 Inhibition of beta-amyloid aggregation Ceased WO2008050133A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07824323A EP2089419A2 (en) 2006-10-27 2007-10-26 Inhibition of beta-amyloid aggregation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85469406P 2006-10-27 2006-10-27
US60/854,694 2006-10-27

Publications (2)

Publication Number Publication Date
WO2008050133A2 WO2008050133A2 (en) 2008-05-02
WO2008050133A3 true WO2008050133A3 (en) 2008-06-19

Family

ID=38962885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/004079 Ceased WO2008050133A2 (en) 2006-10-27 2007-10-26 Inhibition of beta-amyloid aggregation

Country Status (2)

Country Link
EP (1) EP2089419A2 (en)
WO (1) WO2008050133A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611323B2 (en) 2010-11-30 2017-04-04 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127829A1 (en) 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
WO2014184596A2 (en) * 2013-05-17 2014-11-20 Szegedi Tudomanyegyetem SMALL PEPTIDE INHIBITORS OF β-AMYLOID TOXICITY
EP3035969B1 (en) 2013-08-19 2022-08-03 S.M. Discovery Holdings Inc. Peptidic nanodelivery composition targeting two receptors
GB201414038D0 (en) * 2014-08-07 2014-09-24 Univ Sussex The Alzheimer's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (en) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2003018609A2 (en) * 2001-08-23 2003-03-06 Stanley Stein Application of peptide conjugates to alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (en) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2003018609A2 (en) * 2001-08-23 2003-03-06 Stanley Stein Application of peptide conjugates to alzheimer's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRUZ M ET AL: "Inhibition of beta-amyloid toxicity by short peptides containing N-methyl amino acids.", THE JOURNAL OF PEPTIDE RESEARCH : OFFICIAL JOURNAL OF THE AMERICAN PEPTIDE SOCIETY MAR 2004, vol. 63, no. 3, March 2004 (2004-03-01), pages 324 - 328, XP002467773, ISSN: 1397-002X *
KOKKONI NICOLETA ET AL: "N-methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 45, no. 32, August 2006 (2006-08-01), pages 9906 - 9918, XP002419875, ISSN: 0006-2960 *
WOOD S J ET AL: "PROLINES AND AMYLOIDOGENICITY IN FRAGMENTS OF THE ALZHEIMER'S PEPTIDE BETA/A4", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 34, no. 3, 24 January 1995 (1995-01-24), pages 724 - 730, XP002050228, ISSN: 0006-2960 *
ZHANG GUOBAO ET AL: "Multiple-peptide conjugates for binding beta-amyloid plaques of Alzheimer's disease.", BIOCONJUGATE CHEMISTRY 2003 JAN-FEB, vol. 14, no. 1, January 2003 (2003-01-01), pages 86 - 92, XP002467772, ISSN: 1043-1802 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611323B2 (en) 2010-11-30 2017-04-04 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US10941215B2 (en) 2010-11-30 2021-03-09 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses thereof

Also Published As

Publication number Publication date
EP2089419A2 (en) 2009-08-19
WO2008050133A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
WO2008089310A3 (en) Delta 5 desaturase inhibitors for the treatment of obesity
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
LT1854477T (en) Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders.
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2010067078A8 (en) 3,6-disubstituted xanthylium salts
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2008060362A3 (en) Methods and compositions for the treatment of skin diseases and disorders
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
WO2008008884A3 (en) Inhibition of beta-amyloid peptide aggregation
WO2008050133A3 (en) Inhibition of beta-amyloid aggregation
AU2005313582A8 (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
WO2010065861A3 (en) Inhibitors of bace 1 and methods for treating alzheimer's disease
WO2008034735A3 (en) 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2005101968A3 (en) Antisense oligonucleotides against cpla2, compositions and uses thereof
AU2008339005A8 (en) 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2006136454A3 (en) Use of inhibitors of n-methyl transferases for the therapy of parkinson's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824323

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007824323

Country of ref document: EP